Salivary Cortisol As a Biomarker in Patients with Temporomandibular Disorder

StatusUnknown
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
t is recognized that cortisol, a hormone produced by the adrenal glands, is a marker that is elevated in patients with psychological disorders, particularly anxiety. On the other hand, Temporomandibular Disorders (TMD) are a condition with a multifactorial etiology, in which emotional disturbances play a crucial role. Therefore, the aim of this study is to evaluate whether patients with TMD have higher levels of salivary cortisol compared to the general population. Initially, an assessment will be conducted using the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD) protocol to determine whether the patient suffer of any kind of Temporomandibular Disorder. Based on the results, individuals will be classified into two groups: the study group, consisting of patients with TMD, and the control group, composed of individuals without the disorder. Those who agree to participate will be required to sign an informed consent form. Subsequently, a saliva sample will be collected for analysis.
Trial Details
NCT Number NCT06874868
Lead Sponsor University of Coimbra
Conditions
(from sponsor)		 Temporomandibular Joint Disorder
Related terms Temporomandibular Joint Disorders
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov